06 June 2007 /Side effects and trials
During the first two years of a medicinal product's life on the market, adverse reactions are monitored closely. Doctors must report adverse reactions.
08 February 2007 /Side effects and trials
The CHMP-Pharmacovigilance Working Party has considered the safety of gadolinium-containing MRI contrast agents. The Committee has concluded that the recommendations on the use of these contrast agents should be amended for patients with impaired renal function.